Funding for this research was provided by:
National Institute of General Medical Sciences (5P20GM109025)
A Woman's Nation/Maria Shriver (N/A)
National Institutes of Health (U01 AG024904)
Department of Defense (W81XWH-12-2-0012)
Received: 10 March 2017
Accepted: 22 August 2017
First Online: 12 September 2017
Ethics approval and consent to participate
: All data included in this article were collected for research use as part of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) project. ADNI is a longitudinal, multisite AD biomarker study (ExternalRef removed) that offers de-identified data meeting criteria for limited datasets to qualified researchers with scientific or educational institution affiliations, upon review. Ethics approval for data collection in ADNI was obtained by each ADNI participating institution’s institutional review board. All participants gave written informed consent at participating institutions. The authors of this paper were granted approved access to the ADNI data, and the ADNI Data Sharing and Publications Committee (DPC) approved this paper for submission to <i>Alzheimer’s Research and Therapy</i> (date of approval, February 24, 2017).
: Not applicable.
: JZKC, JLB, and SJB declare that they have no competing interests. JLC declares having received in kind research support from Avid Radiopharmaceuticals, Teva Pharmaceuticals, and CogState; having done consultation for AbbVie, ACADIA Pharmaceuticals, Accera, Actinogen Medical, Adamas Pharmaceuticals, Alkahest, Alzheon, Anavex Life Sciences, Astellas Pharma, AstraZeneca, Avanir Pharmaceuticals, Axovant Sciences, Biogen Idec, Biotie Therapies, Boehinger Ingelheim, Chase Pharmaceuticals, Eisai, FORUM Pharmaceuticals, Genentech, Grifols, Intra-Cellular Therapies, Iris Pharma, Ionis Pharmaceuticals, Eli Lilly and Company, Lundbeck, Merck, Neurotrope BioScience, Novartis, Nutricia, Otsuka, Pfizer, Probiodrug, QR Pharma, Resverlogix, Roche, Servier, Sunovion Pharmaceuticals, Suven Life Sciences, Takeda, Taisho Toyama Pharmaceutical Co., Transition Therapeutics, United Neuroscience, GE Healthcare, and MedAvante; owning stock in Adamas Pharmaceuticals, Prana Biotechnology, Sonexa Therapeutics, MedAvante, NeuroTrax, and Neurokos; and owning the copyright of the Neuropsychiatric Inventory. In addition, JLC has provided expert witness/legal consultation regarding olanzapine and ropinerole.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.